Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 4 Irbesartan decreases lipid peroxidation in the serum of patients with coronary artery disease. Serum samples were collected during the 12-week period of treatment at the start of the study (0 weeks) and at 4 and 12 weeks of treatment. The thiobarbituric acid reactive substances (TBARS) assay was performed, as described in the Methods section, using spectrophotometric analysis at 568 nm. The p value, as determined by analysis of variance, was 0.027 for time, 0.012 for the group and 0.004 for the group-time interaction. Black square = placebo; white square = irbesartan; *p < 0.05 = difference between 0 weeks and 4 or 12 weeks within each group; #p < 0.05 = difference between placebo and irbesartan groups.
|
